Novartis (NVS) has seen a high-level of popularity recently, with trading volumes increasing significantly by 61.45%. Furthermore, it scored a beat-and-raise quarter, with its shares reaching a buy point and hitting a fresh high, resulting in its valuation as a top value stock for the long-term. Although its bid to block the US Entresto generic through 2026 was unsuccessful, Novartis positioned itself well amongst investors, with individual investors accounting for 57% of Novartis' ownership. Exciting developments include an infant malaria breakthrough, which is viewed as a strategic play in global health and ESG leadership, and an exclusive option agreement with Sironax to acquire its brain delivery platform. Moreover, Novartis completed the acquisition of Regulus Therapeutics for $1.7 Billion. Deutsche Bank remains optimistic about Novartis' potential and maintained a buy rating. Novartis has also managed to impress with improved first-quarter sales results, which exceeded expectations. This successful quarter led to an increase in full-year guidance. Despite losing some gains due to competition for its key drug, Novartis seems to maintain strong momentum.
Novartis Stocks News Analytics from Tue, 29 Oct 2024 07:00:00 GMT to Fri, 11 Jul 2025 22:16:53 GMT -
Rating 10
- Innovation 2
- Information 10
- Rumor -5
